Bioavailability of Fish Oils: Emulsified Versus Capsular Triglyceride

Bioavailability of Fish Oils: Emulsified vs. Capsular Triglyceride

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01488747

Enrollment

Registered

2011-12-08

Start date

2011-11-30

Completion date

2016-04-30

Last updated

2018-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Adults

Keywords

Omega-3 fatty acids, Phospholipid fatty acids, chymlomicron fatty acids, Bioavailability fo fish oil supplements in healthy adults

Brief summary

The primary objective of this investigation is to determine the relative percentage and rate of incorporation of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and total omega-3 (n-3) fatty acids after ingestion of 4 emulsified flavored triglyceride fish oil supplements versus an encapsulated triglyceride in defined plasma lipid pools. The primary endpoints to be evaluated include the fatty acid composition of plasma lipids before and after consumption of a single dose of emulsified triglyceride based fish oil and triglyceride of similar n-3 compositions in capsule form. The investigators will measure changes in plasma phospholipid, and chylomicron fatty acids.

Interventions

DIETARY_SUPPLEMENTCoromega Omega-3 Squeeze

660 mg EPA, 434 mg DHA

DIETARY_SUPPLEMENTCoromega Nectar

660 mg EPA, 436 mg DHA

DIETARY_SUPPLEMENTBarleans Swirl

660 mg EPA, 660 mg DHA

DIETARY_SUPPLEMENTNordic Omega-3 Softgel

660 mg EPA, 440 mg DHA

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

1. Healthy adults ages 18 to 60. 2. Body mass index between 22 and 32 kg/m2. 3. Medical history (interview) demonstrating good health. 4. Nonsmoker. 5. Consumption of a typical American diet with no unusual dietary habits. 6. Willingness to comply with the study protocol. 7. Low reported n-3 intake (\<100 mg/d) on the Omega-3 Checklist

Exclusion criteria

1. Any active, uncontrolled medical problem. 2. Consumption of essential fatty acid supplements within the past 6 months. 3. Use of lipid lowering drugs. 4. Fish consumption greater than 1 fish meal per week

Design outcomes

Primary

Measure	Time frame	Description
Area under the curve for phospholipid fatty acids	48 hours	Evaluation of the bioavailability of fatty acids from fish oil supplements

Secondary

Measure	Time frame	Description
Area under the curve for chylomicron fatty acids	48 hours	Evaluation of the bioavailability of fatty acids from fish oil supplements

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026